Blood eosinopenia (≤30/µL) as an early predictor of respiratory failure in community-acquired pneumonia: A prospective multicentre study

Read full text
Authors: Barbara Weckler, Roman Martin, Max Kutzinski, Wilhelm Bertrams, Anna Lena Jung, Hendrik Pott, Katrin Laakmann, Leon N. Schulte, Peter Ahnert, Dominik Heider, Stephan Ringshandl, Christian Seidemann
+8 more Suttorp Norbert, Martin Witzenrath, Christian Wildberg, M Lehmann, Gernot Rohde, Timm Greulich, Claus Vogelmeier, Bernd Schmeck
Cited by: 2
References: 20

Abstract

Introduction and objectives Lower blood eosinophil counts have been associated with increased mechanical ventilation rates in patients with community-acquired pneumonia (CAP). However, the optimal eosinophil count threshold for identifying CAP patients at high risk of respiratory failure remains undefined. This study aimed to establish an optimal admission eosinophil count as a prognostic biomarker for respiratory failure in CAP.Methods This prospective, multicentre cohort study (PROGRESS) enrolled adult patients (≥18 years) hospitalised with community-acquired pneumonia (CAP). A receiver operating characteristic curve analysis with Youden’s index was applied to identify the optimal eosinophil threshold for predicting mechanical ventilation. Associations were adjusted for corticosteroid use using multivariable regression. Additional outcomes – ICU admission and hospital length of stay – were compared between patients above and below the optimal eosinophil count threshold.Results An eosinophil count threshold of ≤30/µL was optimal for predicting mechanical ventilation. Patients with eosinophil counts ≤30/µL experienced significantly higher mechanical ventilation rates (15.5% versus 7.3%; p < 0.0001; RR 2.12, 95% CI 1.61–2.80), regardless of glucocorticoid treatment. They also exhibited higher ICU admission rates (23.1% versus 10.9%; p < 0.0001; RR 2.11, 95% CI 1.70–2.63) and longer hospital stays among survivors (median 8.0 versus 7.0 days; p < 0.0001).Conclusions Admission eosinopenia (≤30 µL) is a robust, easily measured biomarker that predicts respiratory failure in hospitalised CAP. It supports early risk stratification and may guide timely escalation of care.

Fields of Study & Subjects

Pneumonia and Respiratory Infections Sepsis Diagnosis and Treatment Chronic Obstructive Pulmonary Disease (COPD) Research

Publication details

Journal / source
Pulmonology
Publisher
Informa UK Limited
Volume
32
Issue
1
Pages
2611215–2611215
Publication date
9 January 2026
Language
EN